Gilead

Gilead develops solid tumour cell therapy with Gadeta

https://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/

Gilead takes ‘HIV eradication’ combo into clinic

https://pharmaphorum.com/news/gilead-takes-hiv-eradication-combo-clinic/

US judge overturns Gilead $2.54bn patent infringement ruling

https://pharmaphorum.com/news-market-access/us-judge-overturns-record-2-54bn-hepatitis-c-drug-ruling/

Cellectis confident on ‘off the shelf’ CAR-Ts despite setbacks

https://pharmaphorum.com/news/pharma-looks-off-shelf-car-ts/

Kymriah gets fast DLBCL review in US and Europe

https://pharmaphorum.com/news/novartis-kymriah-car-t-gets-fast-review-us-eu/

Gilead goes full throttle on CAR-Ts with $567m acquisition

https://pharmaphorum.com/news/gilead-buy-cell-design-labs-567-million/

GSK’s newly approved HIV treatment Juluca expected to dominate

https://pharmaphorum.com/news/fda-approves-gsks-hiv-dual-therapy/

Gilead gains CAR-T approval, undercuts rival’s headline price

https://pharmaphorum.com/news/fda-approves-gilead-car-t-cancer-therapy/

AbbVie, Gilead target sick hepatitis C patients in EU

https://pharmaphorum.com/news/abbvie-gilead-hepatitis-c/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search